Emerging data suggest Retatru tide , a dual agonist targeting both incretin and GIP , appears to offer a significant advancement for obesity management . Initial patient trials have shown impressive decreases in visceral mass , conceivably outperforming existing obesity medications . However , additional assessment is required to fully determine it